Press Releases | Page 15 of 42

Targeting ABC Transporters in PDAC – Past, Present, or Future?

July 10, 2024

“[...] it is crucial for the future application of ABC transporter inhibitors [...] to develop a stratification protocol [...] to identify those PDAC patients who are most likely to benefit… read more

Figure 5: TAS102 in combination with regorafenib inhibits ERK1/2 and STAT3 signaling.

Oncotarget

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers

July 8, 2024

“In this study, we investigated the therapeutic effects and the underlying mechanisms of TAS-102 in combination with regorafenib against gastrointestinal cancers.” BUFFALO, NY- July 8, 2024 – A new research… read more

Oncotarget

Editorial: Genomics Has More to Reveal

July 2, 2024

“If there was any doubt, this discovery demonstrates that genomics, extensively deployed over the past two decades, still has much to reveal to us.” BUFFALO, NY- July 2, 2024 –… read more

Oncotarget

Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response

June 26, 2024

“Depleting amino acid[s] likely expose[s] the Achilles heel of the cancer and exacerbate[s] DNA repair-targeted and immune-based therapy response.” BUFFALO, NY- June 26, 2024 – A new research perspective was… read more

Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.

Oncotarget

Leveraging Gold Nanostars for Precision Laser Interstitial Thermal Therapy

June 24, 2024

“Gold nanostars amplify brain-tumor selective laser interstitial thermal therapy.” BUFFALO, NY- June 24, 2024 – A new editorial paper was published in Oncotarget's Volume 15 on June 14, 2024, entitled,… read more

Oncotarget

Assessment of Serum Tumor Markers CEA, CA-125, and CA19-9 as Adjuncts in Non-small Cell Lung Cancer Management

June 19, 2024

“[...] these inexpensive, widely available tests with rapid turnaround times and relatively short half-lives (CEA, CA-125, and CA19-9) are perfectly situated to serve as adjunctive clinical tools in the management… read more

Oncotarget

When Does a Melanoma Metastasize? Implications for Management

June 18, 2024

“[...] immunotherapy is more likely to be effective at eliminating metastatic disease if the tumor burden is low, making it more logical to treat patients with high-risk melanomas at the… read more

Oncotarget

Oncotarget Sponsors 2024 Ride for Roswell

June 11, 2024

Impact Journals (Oncotarget's publisher) is thrilled to sponsor Team Open Access again in the annual cycling event to end cancer, The Ride for Roswell, on June 22, 2024. BUFFALO, NY-… read more

Figure 5: Effects of drugs on the levels of various proteins involved in DNA repair/DNA damage response.

Oncotarget

Synergistic Cytotoxicity of HDAC and PARP Inhibitors and Decitabine in Pancreatic Cancer Cells: Implications for Novel Therapy

June 5, 2024

“The results provide novel preclinical data that demonstrate synergism between HDACi- and PARPi-mediated inhibition of DNA repair and decitabine in pancreatic cancer [...]” BUFFALO, NY- June 5, 2024 – A… read more

Oncotarget

BTK Inhibitor-related Cardiotoxicity: The Quest for Predictive Biomarkers and Improved Risk Stratification

June 4, 2024

“[...] due to the general lack of robust predictive biomarkers, a standardized risk stratification tool is not utilized in clinical practice – a prime area for research.” BUFFALO, NY- June… read more